Schema for Treatment Plan: 
I. Conventional dose combination on chemotherapy. 
II. Collection of peripheral blood cells between WBC of 
300/mm 3 and 800/mm 3 as back-up for transplant. 
III. Collection of autologous cells from peripheral 
blood and marrow, and in vitro purging. 
IV. Exposure of 30% of peripheral blood and marrow 
cells to the LNL-6 and GIN viruses, respectively. 
PCR for Neo and BCR-ABL will be done before and 
after marking. 
V. TBI, VP-16, and cytoxan therapy. 
VI. Infusion of autologous peripheral blood and marrow 
with PCR for BCR-ABL and Neo on thawed specimen 
before infusion. 
VII. PCR for Neo and BCR-ABL after ANC of 2000/mm 3 is 
achieved. 
VIII. PCR for BCR-ABL and neo at 3 weekly intervals during 
and after recovery at 6 months, and at 6 monthly 
intervals for 4 years and at the time of relapse. 
IX. Interferon maintenance therapy after ANC of 2000/mm 3 
and platelet count of 100,000/mm 3 . 
6.0 PRE-TREATMENT EVALUATION (SEE APPENDIX I) 
6.1 A complete history and physical examination including 
documentation of all measurable disease, especially 
spleen and liver size, signs and symptoms, performance 
status and weight loss. A dental examination is also 
recommended . 
6.2 Laboratory studies include CBC, platelet count, 
differential, SMA 12, liver and renal function tests, 
coagulation studies (PT, PTT, Fibrinogen, FSP) , viral 
serology and cytogenetics. BCR-abl analysis will be 
conducted on the same samples. 
6.3 Peripheral blood and bone marrow aspirate and biopsy for 
morphology, pathology, cytogenetics, and PCR. 
6.4 An EKG and CXR will be performed on all patients. An 
echocardiogram or an MVGA will be done. A urinalysis 
will also be obtained before therapy. 
6.5 Pulmonary function studies with diffusion capacity will 
be done. 
7.0 EVALUATION DURING STUDY (SEE APPENDIX D) 
7.1 CBC, platelet, differential every 1-2 days during the 
initial induction. 
7.2 SMA 12, lytes every three to seven days and as indicated 
additionally. 
[ 868 ] 
Recombinant DNA Research, Volume 15 
